순환 무세포 종양 DNA 시장 : 종양 유형별, 암 유형별, 기술별, 용도별, 지역별

Circulating Cell-Free Tumor DNA Market, by Tumor Type, by Cancer Type by Technology, by Application, and by Region

US $ 4,500 ￦ 6,199,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 7,000 ￦ 9,643,000

PDF (Multi User License)

PDF 보고서를 동일 사업장에서 7명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,000 ￦ 13,777,000

PDF (Enterprise User License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

순환 무세포 종양 DNA 시장은 2025년에는 92억 2,000만 달러로 추정되고, 2032년에는 390억 5,000만 달러에 이를 것으로 예측되며, 2025년부터 2032년까지의 연평균 성장률(CAGR)은 22.9%를 나타낼 것으로 전망됩니다.

보고 범위		보고서 세부정보
기준 연도	2024년	시장 규모(2025년)	92억 2,000만 달러
실적 데이터	2020-2024년	예측 기간	2025-2032년
예측 기간 : 2025-2032년 CAGR :	22.90%	가치 예측(2032년)	390억 5,000만 달러

순환 종양 DNA(ctDNA)는 혈류를 순환하는 악성 세포와 종양의 DNA를 의미합니다. 죽은 세포는 DNA를 포함한 내용물을 혈류로 배출합니다. 순환 종양 DNA(ctDNA)에는 보통 암의 검출에 유용한 유전자 변화가 포함되어 있습니다. 암 검출검사가 치유율이 가장 높은 무증상 초기 단계에서 암을 발견할 수 있다면 그 임상적 유용성은 최대가 됩니다.

시장 역학

제품 포트폴리오를 확대하기 위해 시장 주요 기업이 제품 발매 등의 유기적 성장 전략을 채용하는 경우가 늘어나고 있으며, 예측 기간 중 시장 성장의 원동력이 될 것으로 전망됩니다. 예를 들어, 2022년 7월 차세대 분자 진단 회사인 빌리언투원은 최초의 종양학 액체 생검 제품인 노스스타 셀렉트와 노스스타 리스폰스를 출시한다고 발표했습니다. 이 제품은 현재 일부 학술 암 센터에서 연구용으로 사용할 수 있습니다. 이 패널은 빌리언투원의 독점적인 분자 계수 기술 또는 정량 계수 템플릿(QCT)을 활용하여 실행 가능한 변경 사항을 식별하는 데 주목할 만한 검출 한계를 달성합니다.

본 조사의 주요 특징

• 본 보고서는 세계의 순환 무세포 종양 DNA 시장을 상세하게 분석하여 2024년을 기준연도로 한 예측기간 2025-2032년 시장 규모 및 연간 평균 성장률(CAGR%)을 제공합니다.
• 또, 다양한 부문에 걸친 잠재적인 수익 기회를 밝혀, 이 시장의 매력적인 투자 제안 매트릭스에 대해서 해설했습니다.
• 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품의 상시나 승인, 시장 동향, 지역별 전망, 주요 기업이 채용하는 경쟁 전략 등에 관한 주요 인사이트도 제공합니다.
• 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 실적, 전략 등의 파라미터를 바탕으로 세계의 순환 무세포 종양 DNA 시장 주요 기업 프로파일을 제공합니다.
• 본 보고서로부터의 인사이트에 의해 마케팅 담당자나 기업의 경영진은 향후 제품 발매, 유형 업그레이드, 시장 확대, 마케팅 전술에 관해서 정보에 근거한 의사 결정을 실시할 수 있습니다.
• 이 세계의 순환 무세포 종양 DNA 분석 보고서는 투자자, 공급업체, 제품 제조업체, 판매업자, 신규 참가자, 재무 분석가 등 이 업계의 다양한 이해관계자를 대상으로 하고 있습니다.
• 이해관계자는 세계의 순환 무세포 종양 DNA 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.

목차

제1장 조사의 목적과 전제조건

• 조사 목적
• 전제조건
• 약어

제2장 시장 전망

• 보고서 설명
  • 시장 정의 및 범위
• 주요 요약
• 일관된 기회 맵(COM)

제3장 시장 역학, 규제, 동향 분석

• 시장 역학
  • 성장 촉진요인
  • 성장 억제요인
  • 시장 기회
• 영향 분석
• 주요 하이라이트
• 제품 발매
• 기술의 진보
• PEST 분석
• 규제 시나리오
• 합병과 인수

제4장 세계의 순환 무세포 종양 DNA 시장 - COVID-19의 영향 분석

• 경제에 미치는 영향
• COVID-19 역학
• 수요 및 공급에 미치는 영향

제5장 세계의 순환 무세포 종양 DNA 시장, 종양 유형별(2020-2032년)

• 악성 종양
• 전암 종양

제6장 세계의 순환 무세포 종양 DNA 시장, 암 유형별(2020-2032년)

• 폐암
• 대장암
• 유방암
• 기타

제7장 세계의 순환 무세포 종양 DNA 시장, 기술별(2020-2032년)

• PCR
• 대규모 병렬 시퀀싱
• 단일 핵산 다형성

제8장 세계의 순환 무세포 종양 DNA 시장, 용도별(2020-2032년)

• 암 진단
• 표적 치료
• 예후 적응

제9장 세계의 순환 무세포 종양 DNA 시장, 지역별(2020-2032년)

• 북미
  • 미국
  • 캐나다
• 라틴아메리카
  • 브라질
  • 멕시코
  • 아르헨티나
  • 기타 라틴아메리카
• 유럽
  • 영국
  • 독일
  • 이탈리아
  • 프랑스
  • 스페인
  • 러시아
  • 기타 유럽
• 아시아태평양
  • 중국
  • 인도
  • 일본
  • ASEAN
  • 호주
  • 한국
  • 기타 아시아태평양
• 중동
  • GCC
  • 이스라엘
  • 기타 중동
• 아프리카
  • 북아프리카
  • 중앙아프리카
  • 남아프리카

제10장 경쟁 구도

• Biocept, Inc.
• Illumina, Inc.
• Quest Diagnostics Incorporated
• KURABO INDUSTRIES LTD
• PerkinElmer chemagen Technologie GmbH
• Biodesix
• Guardant Health
• QIAGEN
• Sequenom, Inc.
• Agilent Technologies, Inc.
• Fluxion Biosciences Inc.
• Natera, Inc.
• Agena Bioscience, Inc.
• Paragon Genomics, Inc.
• Lucence Health Inc.
• Eurofins Genomics
• Thermo Fisher Scientific

제11장 섹션

• 조사 방법
• 출판사에 대해

KTH

영문 목차

영문목차

Circulating Cell-Free Tumor DNA Market is estimated to be valued at USD 9.22 Bn in 2025 and is expected to reach USD 39.05 Bn by 2032, growing at a compound annual growth rate (CAGR) of 22.9% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 9.22 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	22.90%	2032 Value Projection:	USD 39.05 Bn

The term circulating tumor DNA (ctDNA) refers to DNA from malignant cells and tumors that circulate in the bloodstream. The nucleus of a cell contains most of the DNA. Cells die and are replaced by new ones as a tumor expands. The broken-down dead cells discharge their contents, including DNA, into the bloodstream. ctDNA are short segments of DNA that are typically less than 200 nucleotides in length. The amount of ctDNA varies from person to person and is influenced by the type of tumor, its location, and, in the case of malignant tumors, the stage of the disease. Circulating tumor DNA (ctDNA) usually contains genetic changes that could be useful for detecting cancer. Other significant uses of ctDNA include prognosis, therapeutic monitoring, and tumor volume estimation. When new cancer detection tests can spot cancer in its earliest, asymptomatic stage, when cure rates are highest, they have the greatest clinical utility. Circulating tumor DNA analysis can help in the early detection of cancer and is also used in providing molecular targeting therapeutics.

Market Dynamics

Increasing adoption of organic growth strategies, such as product launches by key players in the market to expand their product portfolio, is expected to drive market growth over the forecast period. For instance, in July 2022, BillionToOne Inc., a next-generation molecular diagnostics company, announced the launch of its first oncology liquid biopsy products, Northstar Select and Northstar Response. The products are currently available for research use with select academic cancer centers. Northstar Select is a comprehensive pan-cancer somatic mutation profiling panel. Leveraging BillionToOne's proprietary molecular counting technology, or Quantitative Counting Templates (QCTs), the panel achieves a notable limit of detection for the identification of actionable alterations. Meanwhile, Northstar Response is a methylation-based, tissue-agnostic treatment response monitoring assay.

Key features of the study:

• This report provides an in-depth analysis of the global circulating cell-free tumor DNA market, and provides market size (US$ Billion) and Compound Annual Growth Rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global circulating cell-free tumor DNA market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study are Biocept, Inc., Illumina, Inc., Quest Diagnostics Incorporated, KURABO INDUSTRIES LTD, PerkinElmer chemagen Technologie GmbH, Biodesix, Guardant Health, QIAGEN, Sequenom, Inc., Agilent Technologies, Inc., Fluxion Biosciences Inc., Natera, Inc., Agena Bioscience, Inc., Paragon Genomics, Inc., Lucence Health Inc., Eurofins Genomics, Thermo Fisher Scientific.
• Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global circulating cell-free tumor DNA analysis report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global circulating cell-free tumor DNA market

Detailed Segmentation:

• Global Circulating Cell-Free Tumor DNA Market, By Tumor Type:
  • Malignant Tumors
  • Precancerous Tumors
• Global Circulating Cell-Free Tumor DNA Market, By Cancer Type:
  • Lung Cancer
  • Colorectal Cancer
  • Breast Cancer
  • Others
• Global Circulating Cell-Free Tumor DNA Market, By Technology:
  • PCR
  • Massively Parallel Sequencing
  • Single Nucleotide Polymorphism
• Global Circulating Cell-Free Tumor DNA Market, By Application:
  • Cancer Diagnosis
  • Targeting Therapeutics
  • Prognosis Indication
• Global Circulating Cell-Free Tumor DNA Market, By Region:
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • Central Africa
  • North Africa
• Company Profiles
  • Biocept, Inc.
  • Illumina, Inc.
  • Quest Diagnostics Incorporated
  • KURABO INDUSTRIES LTD
  • PerkinElmer chemagen Technologie GmbH
  • Biodesix
  • Guardant Health
  • QIAGEN
  • Sequenom, Inc.
  • Agilent Technologies, Inc.
  • Fluxion Biosciences Inc.
  • Natera, Inc.
  • Agena Bioscience, Inc.
  • Paragon Genomics, Inc.
  • Lucence Health Inc.
  • Eurofins Genomics
  • Thermo Fisher Scientific

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Tumor Type
  • Market Snapshot, By Cancer Type
  • Market Snapshot, By Technology
  • Market Snapshot, By Application
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Key Highlights
• Product Launch
• Technological Advancements
• PEST Analysis
• Regulatory Scenario
• Mergers and Acquisitions

4. Global Circulating Cell-free Tumor DNA Market- COVID-19 Impact Analysis

• Economic Impact
• COVID-19 Epidemiology
• Impact on Supply and Demand

5. Global Circulating Cell-free Tumor DNA Market, By Tumor Type, 2020 - 2032, (US$ Billion)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Malignant Tumors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
• Precancerous Tumors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)

6. Global Circulating Cell-free Tumor DNA Market, By Cancer Type, 2020 - 2032, (US$ Billion)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segments Trends
• Lung Cancer
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
• Colorectal Cancer
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
• Breast Cancer
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)

7. Global Circulating Cell-free Tumor DNA Market, By Technology, 2020 - 2032, (US$ Billion)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segments Trends
• PCR
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
• Massively Parallel Sequencing
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
• Single Nucleotide Polymorphism
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)

8. Global Circulating Cell-free Tumor DNA Market, By Application, 2020 - 2032, (US$ Billion)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Cancer Diagnosis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
• Targeting Therapeutics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
• Prognosis Indication
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)

9. Global Circulating Cell-free Tumor DNA Market, By Region, 2020 - 2032, (US$ Billion)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Regions, 2021-2032
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2020 - 2032, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020 - 2032, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2020 - 2032, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Billion)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2020 - 2032, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020 - 2032, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2020 - 2032, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Billion)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2020 - 2032, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020 - 2032, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2020 - 2032, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Billion)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2020 - 2032, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020 - 2032, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2020 - 2032, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Billion)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2020 - 2032, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020 - 2032, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2020 - 2032, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Billion)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2020 - 2032, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020 - 2032, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2020 - 2032, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (US$ Billion)
    • North Africa
    • Central Africa
    • South Africa

10. Competitive Landscape

• Biocept, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Illumina, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Quest Diagnostics Incorporated
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• KURABO INDUSTRIES LTD
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• PerkinElmer chemagen Technologie GmbH
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Biodesix
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Guardant Health
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• QIAGEN
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Sequenom, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Agilent Technologies, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Fluxion Biosciences Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Natera, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Agena Bioscience, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Paragon Genomics, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Lucence Health Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Eurofins Genomics
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Thermo Fisher Scientific
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies

11. Section

• Research Methodology
• About Us

관련자료